September the 3rd, 2024 – Excellent double digit growth for the well known Croatian JGL pharmaceutical company, with revenue totalling over 127.6 million euros.
As Poslovni Dnevnik/Mladen Miletic writes, the huge Croatian JGL pharmaceutical company, otherwise the largest domestically owned entity of this type, ended the first half of 2024 with double-digit growth compared to the same period last year.
The giant JGL Group’s total revenues amounted to an impressive 127.6 million euros, with their pre-tax profit totalling EUR 20.1 million, representing a record half-year result. Compared to the same period last year, this is a 22.5 percent increase in total revenue. This was highlighted in the semi-annual report on the Croatian JGL pharmaceutical company’s business operations. Operating revenues over the last twelve months for JGL Pharma amounted to 198.8 million euros, while EBITDA MAT reached 39.1 million euros with a 19.7 percent EBITDA MAT margin.
The President of the Board of Directors, Ivo Usmiani, commented on the results and pointed out the following:
“I’d like to thank all the employees of the Croatian JGL pharmaceutical company, as well as many of our partners, customers and suppliers, for this amazing result. The vision that inspires and guides us can be summarised in the statement that we want to be one of the leading international pharmaceutical companies in the development and production of innovative pharmaceutical products in three therapeutic areas: colds and flu, ophthalmology and dermatology.
All of the steps we take – in the development, production and sales segments – are dedicated to the fulfilment of this bigger vision. According to these strategic areas, traditionally the largest share of net sales is in the cold and flu segment, but in recent years we’ve been working much more intensively on diversification and strengthening our sales in other areas. I’m more than glad that these efforts have clearly been fruitful, as the numbers show – in the first half of 2024, and compared to the same period last year, our sales in dermatology grew by as much as 42%, in ophthalmology by as much as 33%.”
